Brief: Resverlogix Receives Ethics Approval For Canadian Sites In Covid-19 Clinical Trial
12/10/2021 21:50
Oct 12 (Reuters) - Resverlogix Corp RVX.TO :
* RESVERLOGIX RECEIVES ETHICS APPROVAL FOR CANADIAN SITES IN
APABETALONE COVID-19 CLINICAL TRIAL
Source text for Eikon: ID:nGNX4d4K61
Further company coverage: RVX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment